Pluristem Therapeutics, an Israeli regenerative medicine company, signed a term sheet for a $30 million investment from China’s Innovative Medical Management. Pluristem develops placental cells using a proprietary, three-dimensional bioreactor to expand cells. The company plans to start a Phase III trial of its PLX-PAD cells for critical limb ischemia in Japan and Europe next year. Innovative Medical, which is active in life science, owns three large hospitals in China along with other life science investments.
